NASDAQ:SGYP - Synergy Pharmaceuticals Stock Price, Price Target & More

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) announced its quarterly earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.01. The biopharmaceutical company earned $8.59 million during the quarter, compared to the consensus estimate of $11.18 million. Synergy Pharmaceuticals had a negative net margin of 773.82% and a negative return on equity of 652.66%. The company's revenue for the quarter was up 776.5% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.30) earnings per share. View Synergy Pharmaceuticals' Earnings History.

8 brokerages have issued 12 month price targets for Synergy Pharmaceuticals' stock. Their forecasts range from $2.50 to $15.00. On average, they expect Synergy Pharmaceuticals' stock price to reach $8.8125 in the next twelve months. This suggests a possible upside of 363.8% from the stock's current price. View Analyst Ratings for Synergy Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synergy Pharmaceuticals in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Synergy Pharmaceuticals saw a decrease in short interest in June. As of June 29th, there was short interest totalling 54,868,105 shares, a decrease of 12.8% from the June 15th total of 62,939,216 shares. Based on an average daily volume of 3,251,186 shares, the days-to-cover ratio is presently 16.9 days. Approximately 22.3% of the company's stock are short sold. View Synergy Pharmaceuticals' Current Options Chain.

Some companies that are related to Synergy Pharmaceuticals include Cambrex (CBM), Mallinckrodt (MNK), Aimmune Therapeutics (AIMT), AnaptysBio (ANAB), PTC Therapeutics (PTCT), Corcept Therapeutics (CORT), IMMURON Ltd/S (IMRN), ARMO Biosciences (ARMO), Pacira Pharmaceuticals (PCRX), G1 Therapeutics (GTHX), Mirati Therapeutics (MRTX), Innoviva (INVA), TherapeuticsMD (TXMD), Arrowhead Pharmaceuticals (ARWR) and Biohaven Pharmaceutical (BHVN).

News coverage about SGYP stock has been trending somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Synergy Pharmaceuticals earned a media sentiment score of 0.10 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 47.24 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Shares of SGYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of SGYP stock can currently be purchased for approximately $1.90.

Synergy Pharmaceuticals has a market capitalization of $473.74 million and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Synergy Pharmaceuticals employs 313 workers across the globe.

Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected]